Chevron Deference Overturned: What's Next for FDA's LDT Oversight
Haydar Celik, PhDPublished on: 02/07/2024
Explore how the Supreme Court's Chevron deference decision could reshape FDA oversight of laboratory developed tests (LDTs), regulatory authority, compliance strategies, and the future of diagnostic innovation.
Chevron deferenceFDALaboratory Developed Tests (LDTs)Regulatory authorityClinical diagnosticsRegulatory strategyComplianceDiagnostic innovation